Anti‐Müllerian hormone for assessing ovarian toxicity of cancer treatment in young women: It’s complicated

The rising incidence of cancer among young women highlights the importance of understanding treatment‐related gonadotoxicity, which can lead to infertility and long‐term health complications from premature estrogen decline. Although anti‐Müllerian hormone is considered the most reliable indicator of ovarian reserve, its interpretation among oncology patients is complex because it is dependent on the treatment modality, necessitating further research to fully understand the impact of specific treatments on anti‐Müllerian hormone and to identify alternative markers to reliably assess the ovarian toxicity of newer cancer therapies.